Hasegawa Kiyoshi, Aoki Taku, Ishizawa Takeaki, Kaneko Junichi, Sakamoto Yoshihiro, Sugawara Yasuhiko, Kokudo Norihiro
Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Ann Surg Oncol. 2014 Jun;21 Suppl 3:S348-55. doi: 10.1245/s10434-014-3585-x. Epub 2014 Feb 25.
There seems to be a consensus in regard to the initial treatment of small hepatocellular carcinomas (HCCs): either percutaneous ablation or liver resection should be selected. Liver resection provides for excellent local control, which is one of the most important factors to be considered in the treatment of HCC. However, percutaneous ablation has the advantage of less invasiveness, which allows for repeated sessions of ablation. However, there has been a longstanding debate on which of the two therapeutic modalities might be superior in individual cases with various tumor-related and liver function factors. Although it is practically difficult to conduct randomized controlled trials (RCTs) to compare these two therapeutic modalities, there have been four RCTs published in English, which we focus on in this review article. We discuss the aforementioned unsolved problem according to the results of these RCTs, in addition to the results of a large-scale cohort study and the recommendations of clinical practice guidelines.
对于小肝细胞癌(HCC)的初始治疗似乎存在共识:应选择经皮消融或肝切除术。肝切除术可实现良好的局部控制,这是HCC治疗中最重要的考虑因素之一。然而,经皮消融具有侵入性较小的优势,这使得可以进行重复消融治疗。然而,对于这两种治疗方式在伴有各种肿瘤相关和肝功能因素的个体病例中哪种可能更具优势,一直存在长期争论。尽管实际上很难进行随机对照试验(RCT)来比较这两种治疗方式,但已有四篇英文发表的RCT,我们在这篇综述文章中重点关注这些研究。除了一项大规模队列研究的结果和临床实践指南的建议外,我们还根据这些RCT的结果讨论上述未解决的问题。